迪哲醫藥(688192.SH):多項血液瘤最新研究進展入選2025歐洲血液學協會年會以及第18屆國際惡性淋巴瘤會議報告
格隆匯5月15日丨迪哲醫藥(688192.SH)公佈,公司將於今年6月舉行的血液學領域兩大國際頂尖學術會議——2025歐洲血液學協會(EHA)年會以及第18屆國際惡性淋巴瘤會議(ICML),公佈其血液腫瘤管線中8項研究的最新臨牀數據。公司核心產品高瑞哲(通用名:戈利昔替尼膠囊)和DZD8586在淋巴瘤領域的研究進展,自今年美國臨牀腫瘤學會(ASCO)年會以來,連續獲得三項口頭報告。
高瑞哲一項II期前瞻性多中心臨牀研究JACKPOT26的最新2年隨訪數據入選本次EHA大會,並同時獲ICML大會口頭報告。該研究旨在評估高瑞哲用於經一線系統性治療後緩解的外周T細胞淋巴瘤(PTCL)維持治療的安全性和有效性。結果顯示,高瑞哲針對經一線治療後的PTCL患者,可有效維持療效並加深腫瘤緩解,且安全性可控。PTCL患者在經過一線標準治療後,約40%的完全緩解(CR)患者和80%的部分緩解(PR)患者在腫瘤緩解後的兩年內會出現疾病進展,患者復發風險高且預後差,目前尚無標準的維持治療方案。今年4月,在最新發布的《中國臨牀腫瘤學會(CSCO)淋巴瘤診療指南(2025版)》中,提及了高瑞哲針對PTCL維持治療的探索。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.